According to the consulting report of Mymes, recently, the industry-leading bio-micro-electromechanical (MEMS) chip independent research and development startup Suzhou In-Situ Chip Technology announced the completion of several million yuan angel round of financing, investment by well-known domestic angel investors. This round of financing is completed. Afterwards, the in-situ chip, with its powerful chip technology, has independent R&D and production capabilities to focus on the emerging bio-MEMS chip market. It will release the country’s first MEMS liquid flow sensor in 2018 and complete MEMS chip insulin pump and PoCT instant blood test chip. A number of promising new biochip development and pilot tests.
Bio MEMS chip - black technology combining semiconductor chips and biotechnology
The biochip produced by the combination of MEMS chip technology and biomedical technology is an emerging technology that US and European countries have only recently begun to research. Currently, many companies in the United States and Europe have invested a lot of R&D resources in this field. Debiotech and STMicroelectronics have already Cooperative R & D launched a chip-type insulin pump, the United States Abbott, Google also has a number of subversive biochip blood test project in research and development.
The microarray-scale mechanical structure and detection reagents are arranged on the silicon-based biochip. The structure size is smaller than a hair filament. The medical device and detection device can be chip-sized, miniaturized, instant, performance is improved, and the cost is extremely low. , will change the existing pattern of medical equipment, China's semiconductor and medical equipment to achieve curve overtaking trillion-scale blue ocean market.
Ma Shuo, CEO of in-situ chip company, said: “With bioMEMS technology, there will be several hundred yuan in-chip insulin pumps within five years. In addition, multiple desktop medical testing devices will be chipped, and blood tests will no longer need to go to the hospital. Patients are at home. A drop of fingertips to a disposable chip, you can enjoy instant blood test, get dozens of biochemical indicators in 5 minutes. '
The country's scientific research investment layout for 20 years, China has its own proprietary bio-MEMS chip
Because of the in-depth combination of the two difficult technologies of semiconductor MEMS technology and biotechnology, the bio-MEMS chip has been left blank for domestic industrial products. However, in the academic field, the Ministry of Science and Technology of the People's Republic of China has already laid out its layout more than 20 years in advance, supporting multiple scientific researches. The research of the project laid a fire for the independent innovation of bio-MEMS chip in China.
The core team of the in-situ chip was originated from the Institute of Microelectronics of Tsinghua University and the Suzhou Nanotechnology Institute of the Chinese Academy of Sciences. Ma Shuo, founder of the company, was a graduate student in 2011. Based on the technical accumulation of the research group, it completed a number of US and European monopoly bio-MEMS chip projects. Research. After completing the research project in 2015, he witnessed the monopoly of imported chips and the backwardness of domestic bio-MEMS chips. The in-situ chip team went to Suzhou to set up the company, relying on the high-quality startup environment and complete MEMS industrial chain resources of Suzhou Industrial Park, and began to struggle. Domestic biochip industrial innovation and entrepreneurship.
With years of accumulation of bio-MEMS chip technology, the company has made rapid progress in the field of difficult bio-MEMS chips, and has developed insulin pump, instant blood test chip, silicon nitride film chip and in-situ chip to break foreign monopoly bio-chips. In this high threshold track, the company’s technology accumulation, R&D team strength, industrial chain resources and patent accumulation have already taken the leading position in China, and it has the ability to overtake U.S. and European countries.
According to the in-situ chip company, the completion of this round of financing is only the first step for the company to start accelerating its development. In the future, the company will continue to cooperate with high-quality capital, aiming to use semiconductor technology and biotechnology to integrate biochips to improve personal medical standards and become Billion-level blue ocean biochip market leader.
Technical team and capital work together, domestic capital increasingly focuses on hard technology innovation
Making hard nuclear technology innovation products is a key shortcoming of China's industrial structure, and it is also a difficult point for transition. European and American countries have blocked China's acquisition of hard technology companies, and only one road has been independently developed for industrial transformation. Ma Shuo puts hard nuclear technology into its own intellectual property products. R&D is like climbing a 1000-meter mountain: 'The first 300 meters of early R&D required the development of national research funds and the support of the research team. After 300 meters of product production can rely on strategic investment and bank loans, and the middle 400 meters of the pilot stage is The most difficult investment in this stage can only rely on the help of venture capital funds, and it is also the stage with the highest multiple investment return. It requires VCs with strong team analysis capabilities, understanding of the competition track and faith in technology innovation. '
The good news is that China’s domestic and early-early funds have increasingly realized the steady development characteristics and great potential of hardcore technology innovation and entrepreneurship. Many funds are moving in this direction. Recently, several agencies announced the establishment of a sub-fund focusing on hard technology innovation. At present, China and the United States compete in the field of scientific and technological innovation. These hard science and technology investment funds will play an extremely important role in the development and industrialization of high-tech products in China.